| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on January 7, 2007
Accepted on May 15, 2007
From the Université Pierre et Marie Curie-Paris 6 (A.K., J.A.d.S., S.C., M.J.C.), Paris; AP-HP, Groupe hospitalier Pitié-Salpétrière (A.K., J.A.d.S., S.C., M.J.C.), Paris; INSERM, Dyslipoproteinemia and Atherosclerosis Research Unit 551 (A.K., P.T., A.Z., M.C., A.N.-S., J.A.d.S., S.C., M.J.C.), Paris; Université Paris Descartes, Department of Biochemistry (P.T., A.Z., M.C.), EA 3617, Paris; and INSERM Unit 466 (A.N.-S.), CHU Rangueil, Toulouse, France.
* To whom correspondence should be addressed. E-mail: kontush{at}chups.jussieu.fr.
Objective--The purpose of this study was to define heterogeneity in the molecular profile of lipids, including sphingomyelin and sphingosine-1-phosphate, among physicochemically-defined HDL subpopulations and potential relevance to antiatherogenic biological activities of dense HDL3.
Methods and Results--The molecular profile of lipids (cholesteryl esters, phospholipids, sphingomyelin, and sphingosine-1-phosphate) in physicochemically-defined normolipidemic HDL subpopulations was determined by high-performance liquid chromatography and gas chromatography. As HDL particle size and molecular weight decreased with increment in density, molar lipid content diminished concomitantly. On a % basis, sphingomyelin abundance diminished in parallel with progressive increase in HDL density from HDL2b (12.8%) to HDL3c (6.2%; P<0.001); in contrast, sphingosine-1-phosphate was preferentially enriched in small HDL3 (40 to 50 mmol/mol HDL) versus large HDL2 (15 to 20 mmol/mol HDL; P<0.01). Small HDL3c was equally enriched in LpA-I particles relative to LpA-I:A-II. The sphingosine-1-phosphate/sphingomyelin ratio correlated positively with the capacities of HDL subspecies to attenuate apoptosis in endothelial cells (r=0.73, P<0.001) and to retard LDL oxidation (r=0.58, P<0.01).
Conclusions--An elevated sphingosine-1-phosphate/sphingomyelin ratio is an integral feature of small dense HDL3, reflecting enrichment in sphingosine-1-phosphate, a key antiapoptotic molecule, and depletion of sphingomyelin, a structural lipid with negative impact on surface fluidity and LCAT activity. These findings further distinguish the structure and antiatherogenic activities of small, dense HDL.
This article has been cited by other articles:
![]() |
A. Zerrad-Saadi, P. Therond, S. Chantepie, M. Couturier, K.-A. Rye, M. J. Chapman, and A. Kontush HDL3-Mediated Inactivation of LDL-Associated Phospholipid Hydroperoxides Is Determined by the Redox Status of Apolipoprotein A-I and HDL Particle Surface Lipid Rigidity: Relevance to Inflammation and Atherogenesis Arterioscler Thromb Vasc Biol, December 1, 2009; 29(12): 2169 - 2175. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Y. Fujimoto, J. P. Kane, B. Y. Ishida, M. S. Bloom, and R. W. Browne High-density lipoprotein metabolism and the human embryo Hum. Reprod. Update, August 28, 2009; (2009) dmp029v2. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. S. Davidson, R.A. G. D. Silva, S. Chantepie, W. R. Lagor, M. J. Chapman, and A. Kontush Proteomic Analysis of Defined HDL Subpopulations Reveals Particle-Specific Protein Clusters: Relevance to Antioxidative Function Arterioscler Thromb Vasc Biol, June 1, 2009; 29(6): 870 - 876. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Sattler and B. Levkau Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection Cardiovasc Res, May 1, 2009; 82(2): 201 - 211. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Carnemolla, X. Ren, T. K. Biswas, S. C. Meredith, C. A. Reardon, J. Wang, and G. S. Getz The Specific Amino Acid Sequence between Helices 7 and 8 Influences the Binding Specificity of Human Apolipoprotein A-I for High Density Lipoprotein (HDL) Subclasses: A POTENTIAL FOR HDL PREFERENTIAL GENERATION J. Biol. Chem., June 6, 2008; 283(23): 15779 - 15788. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Mallat and A. Tedgui HDL, PTX3, and Vascular Protection Arterioscler Thromb Vasc Biol, May 1, 2008; 28(5): 809 - 811. [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |